# Core C - Biomarker and Biobanking Core

> **NIH NIH P01** · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2024 · $407,943

## Abstract

Core C: Biomarker and Biobanking Core—Abstract
The Biomarker and Biobanking Core will provide scientific direction and oversight of biomarker and biobanking
samples for the entire Health, Aging and Dementia in South Africa: A Longitudinal Study (HAALSI)
Program. The Core is led by two Co-PIs who will oversee a group of international experts in the fields of
epidemiology, genomics, bioinformatics, epigenetics, biostatistics, and biomarker analysis. A biomarker is
defined by NIH as a characteristic that is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. We
further divide biomarkers into two broad categories for the purpose of Core C: (1) those that do not require a
biological sample to be collected and/or stored (e.g., imaging, blood pressure); and (2) those that require a
biological sample to be further analyzed, whether at the point of care (e.g., blood glucose) or in a laboratory
(e.g., urine sodium, DNA).This Core will allow us to continue our commitment to longitudinal sample collection
in Agincourt and the coordinated use of biomarkers across all four research projects. The proposed HAALSI
National survey will augment the HAALSI Agincourt community study with biomarker data from a nationally
representative cohort. The growing collection of baseline and new biomarker data related to dementia,
cognitive function, cardiometabolic diseases, HIV, and inflammation will inform many research questions and
provide opportunities for comparative data for analyses. In particular, we are collecting and analyzing novel
biomarkers for dementia and heart failure that have not been measured extensively in African populations.
Neuroimaging and plasma samples for amyloid beta (Aβ), phosphorylated tau (p-tau), neurofilament light chain
(NfL), and glial fibrillary acidic protein (GFAP) will allow for improved phenotyping and relationships between
risk factors for dementia. Further, novel cardiac biomarkers of echocardiography and plasma levels of NT-pro
brain natriuretic peptide (BNP), cardiac troponin I, and Galactin-3 will be measured for longitudinal evaluation
for the first time in an African cohort, allowing for improved phenotyping and risk stratification for
cardiometabolic disease morbidity and mortality.

## Key facts

- **NIH application ID:** 10843293
- **Project number:** 5P01AG041710-10
- **Recipient organization:** HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH
- **Principal Investigator:** Michele Michele Ramsay
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $407,943
- **Award type:** 5
- **Project period:** 2013-09-15 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10843293

## Citation

> US National Institutes of Health, RePORTER application 10843293, Core C - Biomarker and Biobanking Core (5P01AG041710-10). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10843293. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*